INVVY News and Press, Indivior PLC ADR From 04/13/18

SLOUGH, United Kingdom and RICHMOND, Va. , April 13, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the presentation of results from RB-US-13-0003, a study which evaluated long-term treatment with once-monthly SUBLOCADE™ (buprenorphine extended-release) inject...

SLOUGH, England and RICHMOND, Va. , April 11, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will release its first quarter 2018 results on May 2 nd at 12:00 p.m. London time ( 7:00 a.m. U.S. Eastern). The results will be available via the London Stoc...

SLOUGH, England and RICHMOND, Va. , March 29, 2018 /PRNewswire/ -- Indivior PLC ("Indivior") (LON: INDV) today announced that its subsidiary Indivior UK Limited ("Indivior UK") and C4X Discovery Holdings PLC ("C4X") (AIM: C4XD) entered into a license agreement whereby Indivio...

Insys ( INSY ) reported Q4 revenue of $31.5 million and eps of -$0.61. The company missed on revenue by $2.5 million and missed on eps by $0.47. However, the quarter was not all bad for Insys. Revenue Appears To Be Stabilizing Insys manufactures and markets two main drugs - subsys and sy...

SLOUGH, England and RICHMOND, Va. , March 1, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that S UBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use (CIII), is now available in the United States . SUBLOCADE is approved by the U...

Indivior PLC ADR (INVVY) Q4 2017 Earnings Conference Call February 15, 2018 7:00 AM ET Executives Shaun Thaxter - Chief Executive Officer Mark Crossley - Chief Financial Officer Javier Rodriguez - Chief Legal Officer Christian Heidbreder - Chief Scientific Officer Analysts ...

The following slide deck was published by INDIVIOR PLC ADR in conjunction with their 2017 Q4 earnings Read more ...

Indivior PLC ADR ( OTCPK:INVVY ): Q4 EPS of $0.07 More news on: INDIVIOR PLC ADR, Earnings news and commentary, Healthcare stocks news, Read more ...

SLOUGH, England , Feb. 8, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. Reddy's, Actavis, Par, Alvogen and Teva for infringement of United States Pate...

SLOUGH, England and RICHMOND, Va. , Jan. 19, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will release its full year 2017 results on February 15 th at 7:00 a.m. London time ( 2:00 a.m. U.S. EST). The results will be available via the London Stock...